Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...
DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...
DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes ...
Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...
Continuous glucose monitors — the tiny sensors once reserved for people with diabetes — are now appearing on the arms of ...
Dexcom CGM systems provide automatic blood glucose updates every five minutes. FreeStyle Libre sensors can last up to 15 days and no longer need frequent scanning for updates. Both Dexcom and ...
After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback